Andreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.
Andreas Saltos, MD
Advertisement
Articles by Andreas Saltos, MD
Andreas Saltos, MD, discusses the importance of broad molecular testing in non–small cell lung cancer.
Advertisement
Latest Updated Articles
Dr. Saltos on the Importance of Broad Molecular Testing in NSCLCPublished: April 30th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5